More Videos
SPECIAL REPORT
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Should Homeowners Be Able To Walk Away From Mortgage?
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Governments Must Take Steps To Avoid More Dubais: El-Erian
- Black Friday Sales Disappoint Investors; Amazon Up
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Notre Dame Fires Charlie Weis After 5 Seasons
- Get Paid Six Figures to Wear a T-Shirt?
- Nov. 30: Unusual Volume Leaders
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
- Dubai World to Restructure About $26 Billion of Debt
- Lesson From Dubai: Start Cutting Risk In Your Portfolio
- Iranian Seizure of British Yacht Pushes Oil Above $77
- Should Homeowners Be Able to Stop Paying Mortgage?
- Buffett's Predictions For Next Year—And Every Year
- The World's Biggest Debtor Nations
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Fed Tweaking Plan to Pull Money Back out of Economy
- Scientists Gone Wild: Climate Debate Turns Nasty
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
AP |
Sept. 5th-8th the Department of Defense's Prostate Cancer Research Program will hold its conference called the 2007 Innovative Minds in Prostate Cancer Today, or IMPaCT for short, in Atlanta.
On Sept. 27th and 28th the National Prostate Cancer Coalition will hold its annual Advocacy Day (actually, it's two days) in Washington, DC.
And on September 18th Provenge proponents announced today that they will be holding "A Right To Live Day" at Food and Drug Administration headquarters in Rockville, MD. On its Web site, www.arighttolive.com, the organization says it's an "all-volunteer advocacy group", but doesn't divulge whether its base is made up of patients, their advocates, and/or investors. Scott Riccio, the founding member of Right to Live, told me over the phone the group is made up of all three stakeholders. He says he does not own DNDN shares.
The group will be protesting the FDA's controversial delay in the potential approval of Dendreon's [DNDN
Loading...
()
] Provenge. Riccio is quoted in a press release saying, "It has become very clear over the past few years that the FDA has instituted a decelerated approval process for cancer therapies....There has never been such an incredible, irrational and unjustifiable denial of rights of dying patients by such a dysfunctional agency."
This protest follows two small demonstrations in Washington and in Chicago at the American Society of Clinical Oncology meeting last June.
The FDA says it makes decisions about whether to approve or reject drugs based solely on the scientific evidence--the clinical trial data. In the case of Provenge, the agency has asked for the results of an ongoing, larger study aimed directly at determining if the drugs extends patients' lives and, if so, by how much. The preliminary data are expected, at the earliest, the middle of next year.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes